Literature DB >> 26254760

Survival and right ventricular performance for matched children after stage-1 Norwood: Modified Blalock-Taussig shunt versus right-ventricle-to-pulmonary-artery conduit.

Travis J Wilder1, Brian W McCrindle2, Alistair B Phillips3, Eugene H Blackstone4, Jeevanantham Rajeswaran4, William G Williams1, William M DeCampli5, Jeffrey P Jacobs6, Marshall L Jacobs7, Tara Karamlou8, Paul M Kirshbom9, Gary K Lofland10, Gerhard Ziemer11, Edward J Hickey12.   

Abstract

OBJECTIVE: Early survival advantages after Norwood with right-ventricle-(RV)-to-pulmonary-artery conduit (NW-RVPA) over Norwood-operation with a Blalock-Taussig shunt (NW-BT) are offset by concerns regarding delayed RV dysfunction. We compared trends in survival, RV dysfunction, and tricuspid valve regurgitation (TR) between NW-RVPA and NW-BT for propensity-matched neonates with critical left ventricular outflow tract obstruction (LVOTO).
METHODS: In an inception cohort (2005-2014; 21 institutions), 454 neonates with critical LVOTO underwent Norwood stage 1. Propensity-score matching paired 169 NW-RVPA patients with 169 NW-BT patients. End-states were compared between NW-RVPA and NW-BT using competing-risks, multiphase, parametric, hazard analysis. Post-Norwood echocardiogram reports (n = 2993) were used to grade RV dysfunction and TR. Time-related prevalence of ≥moderate RV dysfunction and TR were characterized using nonlinear mixed-model regression, and compared between groups via multiphase, parametric models.
RESULTS: Overall 6-year survival was better after NW-RVPA (70%) versus NW-BT (55%; P < .001). Additionally, transplant-free survival during this time was better after NW-RVPA (64%) versus NW-BT (53%; P = .004). Overall prevalence of ≥moderate RV dysfunction reached 11% within 3 months post-Norwood. During this time, RV dysfunction after NW-BT was 16% versus 6% after NW-RVPA (P = .02), and coincided temporally with an increased early hazard for death. For survivors, late RV dysfunction was <5% and was not different between groups (P = .36). Overall prevalence of ≥moderate TR reached 13% at 2 years post-Norwood and was increased after NW-BT (16%) versus NW-RVPA (11%; P = .003). Late TR was similar between groups.
CONCLUSIONS: Among propensity-score-matched neonates with critical LVOTO, NW-RVPA offers superior 6-year survival with no greater prevalence of RV dysfunction or TR than conventional NW-BT operations.
Copyright © 2015 The American Association for Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Norwood operation; congenital heart disease; critical left ventricular outflow tract obstruction; hypoplastic left heart syndrome; single ventricle

Mesh:

Year:  2015        PMID: 26254760     DOI: 10.1016/j.jtcvs.2015.06.069

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  The Optimal Timing of Stage-2-Palliation After the Norwood Operation.

Authors:  James M Meza; Edward Hickey; Brian McCrindle; Eugene Blackstone; Brett Anderson; David Overman; James K Kirklin; Tara Karamlou; Christopher Caldarone; Richard Kim; William DeCampli; Marshall Jacobs; Kristine Guleserian; Jeffrey P Jacobs; Robert Jaquiss
Journal:  Ann Thorac Surg       Date:  2017-08-25       Impact factor: 4.330

Review 2.  Hypoplastic left heart syndrome: current perspectives.

Authors:  Christopher E Greenleaf; J Miguel Urencio; Jorge D Salazar; Ali Dodge-Khatami
Journal:  Transl Pediatr       Date:  2016-07

3.  Impact of Hybrid Stage 1 Palliation for Hypoplastic Left Heart Syndrome: Histopathological Findings.

Authors:  Takashi Kido; Takaya Hoashi; Masataka Kitano; Masatoshi Shimada; Kenichi Kurosaki; Hatsue Ishibashi-Ueda; Hajime Ichikawa
Journal:  Pediatr Cardiol       Date:  2018-03-09       Impact factor: 1.655

4.  Survival to Stage II with Ventricular Dysfunction: Secondary Analysis of the Single Ventricle Reconstruction Trial.

Authors:  Emilie Jean-St-Michel; James M Meza; Jonathon Maguire; John Coles; Brian W McCrindle
Journal:  Pediatr Cardiol       Date:  2018-03-08       Impact factor: 1.655

Review 5.  Regenerative medicine therapy for single ventricle congenital heart disease.

Authors:  Chetan Ambastha; Gregory J Bittle; David Morales; Nathaniel Parchment; Progyaparamita Saha; Rachana Mishra; Sudhish Sharma; Alexander Vasilenko; Muthukumar Gunasekaran; Manal T Al-Suqi; Deqiang Li; Peixin Yang; Sunjay Kaushal
Journal:  Transl Pediatr       Date:  2018-04

6.  Hypoplastic left heart syndrome: a review.

Authors:  Roberts Gobergs; Elza Salputra; Ingūna Lubaua
Journal:  Acta Med Litu       Date:  2016

Review 7.  Hypoplastic left heart syndrome: from comfort care to long-term survival.

Authors:  Mouhammad Yabrodi; Christopher W Mastropietro
Journal:  Pediatr Res       Date:  2016-10-04       Impact factor: 3.756

8.  Impact of Left Ventricular Morphology on Adverse Outcomes Following Stage 1 Palliation for Hypoplastic Left Heart Syndrome: 20 Years of National Data From Sweden.

Authors:  Katrin Fricke; Mats Mellander; Katarina Hanséus; Phan-Kiet Tran; Mats Synnergren; Jens Johansson Ramgren; Annika Rydberg; Jan Sunnegårdh; Magnus Dalén; Gunnar Sjöberg; Constance G Weismann; Petru Liuba
Journal:  J Am Heart Assoc       Date:  2022-03-29       Impact factor: 6.106

9.  Apples to oranges: Making sense of hybrid palliation for hypoplastic left heart syndrome.

Authors:  Travis J Wilder; Christopher A Caldarone
Journal:  JTCVS Open       Date:  2020-10-15

Review 10.  Resource and cost considerations in treating hypoplastic left heart syndrome.

Authors:  Miguel Urencio; Chris Greenleaf; Jorge D Salazar; Ali Dodge-Khatami
Journal:  Pediatric Health Med Ther       Date:  2016-11-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.